

# Provider Bulletin

Molina Healthcare of Virginia, LLC.

July 3, 2024

## Updated GLP-1 Agonists Requirements for Diabetes Authorization

The Virginia Department of Medical Assistance Services (DMAS) will now require a documented diagnosis of type 2 diabetes mellitus for all GLP-1 Agonists (i.e., preferred and nonpreferred) within the DMAS Closed Class Incretin Diabetes Hypoglycemics: Injectable and Oral Incretin Mimetics used for the treatment of type 2 diabetes mellitus.

In addition to the current clinical criteria required for the nonpreferred agents, members must also have a documented diagnosis of type 2 diabetes mellitus for the preferred agents (i.e., Byetta™, Trulicity®, or Victoza®).

### Questions?

If you have any questions or need clarification, please contact Molina's Provider Contact Center at **(800) 424-4518** or your dedicated Molina Provider Services representative at [MCCVA-Provider@MolinaHealthcare.com](mailto:MCCVA-Provider@MolinaHealthcare.com). They are here to assist you.

Thank you,

Molina Healthcare